Latest News
-
SAN CARLOS, Calif. – ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or... -
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen and is under Priority Review for patients with asthma in the US. The FDA grants...
-
Autologous hematopoietic stem cell transplant (HSCT) provides a long-term survival benefit, when compared with interferon (IFN)-alfa maintenance, in patients with advanced mantle cell lymphoma (MCL), according to research published in The Lancet Haematology.¹ Prior results from this study showed a progression-free survival (PFS) benefit with autologous HSCT, but it wasn’t...
Videos
Rare disease spotlight
Further delineation and long-term evolution of electroclinical phenotype in Mowat Wilson Syndrome. A longitudinal study in 40 individuals http://dlvr.it/S9jctL
Good luck and a huge thank you to all of our @camraredisease runners in the @CambridgeHalfUK today!!!
Out with their #RareBears RUNNING FOR RARE - give them a whoop if you see them!
There’s still time to drop a few quid in their fundraising pot https://www.justgiving.com/fundraising/ivan-christian
